INS and obesity disorder: Current standard-of-care for obesity and T2DM (Pahan 2006) includes lipid-lowering medications (statins, peroxisomal β pathway stimulators, intestinal cholesterol absorption inhibitors), and, before insulin injections become necessary, oral hypoglycemic agents (insulin sensitizers and secretagogues, delaying agents of gut carbohydrates absorption).